Novo Nordisk's Strategic Pivot Faces Crucial First-Quarter Test
Published on 04/20/2026 at 15:02 | Redaktion boerse-global.de
Novo Nordisk shares, trading near 34.34 EUR, are under significant pressure, having shed roughly 20 percent of their value since the start of the year. This decline sets a tense backdrop for the Danish pharmaceutical giant’s upcoming first-quarter report on May 6th. Investors are looking for signs that the company’s multi-pronged strategic response to fierce competition and internal restructuring is beginning to bear fruit.
The competitive landscape shifted decisively in April when Eli Lilly launched Foundayo, the brand name for its oral obesity drug Orforglipron, in the United States. This ended Novo Nordisk’s brief monopoly in the oral GLP-1 market. In response, Novo has aggressively promoted data from an indirect comparison study. The analysis, presented at the Obesity Medicine Association 2026 conference, showed that oral Wegovy (semaglutid) achieved a 13.6 percent mean weight loss over 64 weeks, compared to 11.2 percent for Lilly’s drug over 72 weeks. Perhaps more tellingly, the study indicated patients discontinued treatment due to side effects approximately 14 times more frequently with Orforglipron than with the Wegovy pill.
Novo Nordisk also emphasizes its established safety profile, arguing that the active ingredient in its oral therapy is identical to its long-marketed injectable version, providing a depth of real-world data Lilly must still build for its new molecule. The FDA approved Orforglipron for obesity just one day before Novo’s comparative data was released, adding a layer of strategic timing to the exchange.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Internally, CEO Mike Doustdar is steering a complex organizational overhaul. Following workforce reductions affecting about ten percent of staff in 2025, the company is now in a targeted hiring phase. It plans to bring on around 2,000 new employees this year, with roughly 1,400 already onboard—398 of them in Denmark. However, with total headcount stable at approximately 69,500, this represents a reshuffling rather than net growth. The natural annual employee turnover of around five percent absorbs much of the churn, with new hires focused on production, research, and commercial functions supporting core therapies.
This restructuring has not been without cost. The departure of key figures, including scientist Lotte Bjerre Knudsen, who was instrumental in developing GLP-1 therapies, has raised eyebrows among observers. Concurrently, Doustdar is investing in technology, notably a partnership with OpenAI aimed at boosting researcher productivity and potentially slowing future hiring needs.
Financially, the company’s outlook for 2026 remains constrained. It forecasts sales and operating profit, at constant exchange rates, to fall by around one percent and grow by eleven percent on a reported basis, respectively. Against this sobering forecast, the company is executing a substantial share buyback program. The initiative, worth up to 15 billion Danish kroner over twelve months, has seen nearly 11 million B-shares repurchased by April 10th at an average price of 257.56 DKK, for a total transaction value of approximately 2.84 billion DKK. This represents about 0.6 percent of the share capital.
Technically, the stock’s Relative Strength Index (RSI) hovering around 25 suggests oversold conditions, hinting at short-term recovery potential, though it guarantees no lasting trend reversal. All eyes are now on the May 6th earnings release. The market will scrutinize the initial traction of the oral Wegovy pill and seek early evidence that the streamlined cost structure is delivering measurable savings. How quickly Lilly’s Foundayo gains prescription market share will serve as a critical benchmark, determining whether the stock’s steep decline has fully priced in the new competitive reality or if further pressure lies ahead.
Ad
Novo Nordisk Stock: New Analysis - 20 April
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
